Biotech darling CSL tumbled 16% after it slashed its full-year 2026 outlook and flagged a $5 billion impairment. The stock dragged the healthcare index 6.5% lower to an over eight-year low.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets